Christian Heidbreder Biography and Net Worth

Chief Scientific Officer of Indivior

Christian has served as our CSO since the company’s formation. He brings over 35 years of experience in the neurosciences and has authored more than 500 peer-reviewed publications and conference proceedings, with over 12,000 citations.

Before transitioning to industry, Christian spent a decade in academia, holding research and teaching positions at the National Institute on Drug Abuse (NIDA), and the Swiss Federal Institute of Technology (ETH).

Over the past 25 years, he has held senior leadership roles at SmithKline Beecham, GSK, Altria’s Health Sciences, and Reckitt Benckiser. He is an Affiliate Professor at VCU’s School of Medicine and served on both the National Advisory Council on Drug Abuse and the NIH’s HEAL Multi-Disciplinary Working Group. Christian holds bachelor’s, master’s, and PhD degrees from the University of Louvain, and completed executive studies at Wharton.

What is Christian Heidbreder's net worth?: The estimated net worth of Christian Heidbreder is at least $8.47 million as of July 10th, 2026. Dr. Heidbreder owns 209,337 shares of Indivior stock worth more than $8,467,682 as of July 22nd. This net worth estimate does not reflect any other investments that Dr. Heidbreder may own. Learn More about Christian Heidbreder's net worth.
How do I contact Christian Heidbreder?: The corporate mailing address for Dr. Heidbreder and other Indivior executives is 10710 Midlothian Turnpike, North Chesterfield, VA 23235, United States. Indivior can also be reached via phone at 804-379-1090 and via email at [email protected]. Learn More on Christian Heidbreder's contact information.
Has Christian Heidbreder been buying or selling shares of Indivior?: Over the course of the past ninety days, Christian Heidbreder has sold $764,628.04 in shares of Indivior stock. Most recently, Christian Heidbreder sold 18,586 shares of the business's stock in a transaction on Friday, July 10th. The shares were sold at an average price of $41.14, for a transaction totalling $764,628.04. Following the completion of the sale, the insider now directly owns 209,337 shares of the company's stock, valued at $8,612,124.18. Learn More on Christian Heidbreder's trading history.
Who are Indivior's active insiders?: Indivior's insider roster includes Christian Heidbreder (Chief Scientific Officer), Keith Humphreys (Director), Stuart Kingsley (Director), Daniel Ninivaggi (Director), Ryan Preblick (CFO), Barbara Ryan (Director), Mark Stejbach (Director), and David Wheadon (Director). Learn More on Indivior's active insiders.
Are insiders buying or selling shares of Indivior?: In the last twelve months, Indivior insiders bought shares 7 times. They purchased a total of 5,842 shares worth more than $203,342.45. In the last twelve months, insiders at the sold shares 2 times. They sold a total of 54,586 shares worth more than $2,121,828.04. The most recent insider tranaction occured on July, 10th when insider Christian Heidbreder sold 18,586 shares worth more than $764,628.04. Insiders at Indivior own 0.7% of the company. Learn More about insider trades at Indivior.
Information on this page was last updated on 7/10/2026.

Christian Heidbreder Insider Trading History at Indivior

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/10/2026	Sell	18,586	$41.14	$764,628.04	209,337

Christian Heidbreder Buying and Selling Activity at Indivior

Indivior Company Overview

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Today's Range

Now: $40.09

$39.87

$40.39

50 Day Range

MA: $38.70

$33.71

$41.83

2 Week Range

Now: $40.09

$16.13

$42.81

Volume

42,101 shs

Average Volume

2,168,070 shs

Market Capitalization

$4.89 billion

P/E Ratio

20.68

Dividend Yield

N/A

Beta

0.86